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Review
Modulation of three key innate immune pathways
for the most common retinal degenerative diseases
Isha Akhtar-Schäfer1, Luping Wang2, Tim U Krohne2,† , Heping Xu3,† & Thomas Langmann1,4,†,*
Abstract
This review highlights the role of three key immune pathways in
the pathophysiology of major retinal degenerative diseases includ-
ing diabetic retinopathy, age-related macular degeneration, and
rare retinal dystrophies. We first discuss the mechanisms how loss
of retinal homeostasis evokes an unbalanced retinal immune reac-
tion involving responses of local microglia and recruited macro-
phages, activity of the alternative complement system, and
inflammasome assembly in the retinal pigment epithelium.
Presenting these key mechanisms as complementary targets, we
specifically emphasize the concept of immunomodulation as
potential treatment strategy to prevent or delay vision loss.
Promising molecules are ligands for phagocyte receptors, specific
inhibitors of complement activation products, and inflammasome
inhibitors. We comprehensively summarize the scientific evidence
for this strategy from preclinical animal models, human ocular
tissue analyses, and clinical trials evolving in the last few years.
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Introduction
Diabetic retinopathy (DR) and age-related macular degeneration
(AMD) are the two most frequent retinal degenerative and neovas-
cular diseases in the developed world. While the former is an end-
stage diabetic complication and leading cause of visual impairment
among working-age adults, the latter is the most common cause of
blindness in the elderly, especially among Caucasians. Around one-
third of the population is diagnosed with diabetes, with one-tenth
having vision-threatening disease course which includes diabetic
macular edema (DME) or proliferative diabetic retinopathy (PDR;
Ting et al, 2016). Also alarming are the epidemiologic facts about
AMD with more than 150 million people worldwide suffering from
early forms and around 10 million people developing the late stages
which are geographic atrophy (GA) and neovascular AMD (Wong
et al, 2014). Characteristic for DR and the neovascular form of AMD
is blood vessel growth from the subretinal space into the retina. The
vascular network not only forms in an unregulated manner, but also
becomes leaky. New vessel formation is driven by the angiogenic
factor vascular endothelial growth factor (VEGF), and hence, both
diseases are treated with intravitreal injections of VEGF inhibitors;
however, treatment success is not guaranteed (Cummings & Cunha-
Vaz, 2008). Moreover, no treatment options are currently available
for patients suffering from GA. Another group of blinding diseases
lacking established therapeutic options are inherited retinal degener-
ations, such as retinitis pigmentosa (RP). RP is the most frequent
monogenic photoreceptor degenerating disease with an estimated
prevalence of 1:4,000 (Haim, 2002).
The vertebrate retina is a highly organized layered structure with
more than 60 distinct cell types (Masland, 2001; Hoon et al, 2014).
Both the highly active photoreceptor cells and the phagocytic retinal
pigment epithelium cells (RPE) contribute to the generation of meta-
bolic by-products (Chiu & Taylor, 2011; Datta et al, 2017). With
increasing age, there is a decline in functionality of retinal cells
(Damani et al, 2011; Mitter et al, 2014). Hence, the cells are less
effective in dealing with the accumulating metabolic waste (Wang
et al, 2009; Mitter et al, 2014). Moreover, the decline in functional-
ity is accompanied by a drop in efficacy, for instance, of the RPE to
phagocyte shedded photoreceptor debris (Nandrot et al, 2004; Gu
et al, 2012; Mazzoni et al, 2014). Throughout lifetime, this complex
organ is challenged by a variety of noxious insults including hypox-
ia, hyperglycemia, and inherited mutations (Fritsche et al, 2016;
Masuda et al, 2017). These circumstances demand constant surveil-
lance of the retina for the detection and defense against pathologic
perturbation. To meet this demand, the retina is equipped with a
highly sensitive innate immune system. This immune system
includes (i) surveilling microglia cells, which migrate to the site of
damage and phagocyte apoptotic material (Karlstetter et al, 2015),
(ii) activation of the complement system to opsonize cellular debris
(Xu & Chen, 2016), and (iii) inflammasome assembly in the RPE
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(Doyle et al, 2012; Gao et al, 2015). When not tightly controlled,
these immune pathways pose threat to the surrounding host tissue.
Hence, a cross-talk with Mu¨ller cells and retinal neurons through
the release of regulatory molecules, including complement factors,
chemokines, and neurotrophic factors, limits overt immune activa-
tion in the healthy retina (Harada et al, 2002; Langmann, 2007;
Wolf et al, 2013). In the event of a transient imbalance in retinal
physiology, rapid activation of the immune response will induce
restoration of tissue homeostasis and function. However, in case of
persistent insult, chronic over-activation of the inflammatory
response can lead to devastating tissue remodeling (Chen & Xu,
2015). Pro-inflammatory factors such as reactive oxygen species
(ROS), TNF-a, and CCL2 as well as complement activators such as
C1q are released into the cytosol by overly active microglia (Scholz
et al, 2015a; Madeira et al, 2018). Furthermore, microglia over-
express the anaphylatoxin receptors C5aR and C3aR, while comple-
ment inhibitors such as CFH and CFI are downregulated (Zipfel &
Skerka, 2009; Guillonneau et al, 2017; Madeira et al, 2018).
Complement factors also act as enhanced triggers for inflammasome
assembly, which leads to the activation of the pro-inflammatory
cytokines pro-IL-1b and pro-IL-18 (Nebel et al, 2017; Madeira et al,
2018). The resulting chronic inflammatory response is associated
with a decline in RPE function and structure, breach of the blood–
retina barrier (BRB), new vessel formation, and recruitment of chor-
oidal macrophages (Donoso et al, 2006; Liu et al, 2013; Sato et al,
2018). Hence, these circumstances necessitate therapy approaches
targeting the malfunctioning immune response. Therefore, inhibit-
ing sustained inflammation represents a plausible therapeutic target
to treat a broad range of retinal pathologies (Langmann, 2007).
Here, we comprehensively summarize the role of the three key
innate immune pathways in the most common retinal degenerative
diseases. Furthermore, we comment on recent developments in
preclinical models targeting these pathways and summarize the
current status of clinical trials.
Targeting mononuclear phagocytes in retinal
degenerative diseases
Mononuclear phagocytes in the healthy and diseased retina
Cells of the mononuclear phagocyte (MP) lineage include circulating
blood monocytes, tissue-resident macrophages, dendritic cells, and
microglia (Chow et al, 2011). These cells can be differentiated by
their ontogeny, location, function, and phenotype (Guilliams et al,
2014). MP ontogeny is a research area with much controversy;
however, fate-mapping studies have established that unlike blood-
borne monocyte-derived macrophages, microglia originate from
primitive myeloid progenitors in the extra-embryonic yolk sac
which migrate into the CNS before the blood–brain barrier (BBB) is
established (Ginhoux et al, 2010). Once the tissue is matured, the
self-renewing microglia population is maintained in the brain
parenchyma and the retina throughout the entire life span where
they compose the resident immune cells (Re´u et al, 2017). Interest-
ingly, in the adult retina, microglia replenish from two distinct
extra-retinal sources as shown by pharmacologic depletion using
the selective CSF1R inhibitor PLX5622 (Huang et al, 2018a). Unlike
brain microglia, the cells in the retina were not repopulated from
nestin-positive precursors (Huang et al, 2018b). Instead, replenished
microglia in the retina displayed a dual extra-retinal origin and long-
distance migration ability. First, the residual microglia in the optic
nerve repopulate the retina along the center-to-periphery axis, and
second, macrophages from the ciliary body and iris relocate to the
periphery and migrate toward the center. Furthermore, repopulated
microglia fully restore the broad functionalities of naive microglia
Glossary
Fate-mapping
A method applied in developmental biology, for understanding the
embryonic origin of tissues in the adult organism by investigating the
correspondence between individual cells (or groups of cells) at one
stage of development, and their progeny at later stages.
Geographic atrophy (GA)
An advanced form of AMD characterized by the presence of atrophic
lesions of the outer retina, resulting from loss of photoreceptors,
retinal pigment epithelium (RPE), and underlying choriocapillaris.
Humanized antibodies
Antibodies from non-human species whose protein sequences have
been modified to increase their similarity to antibody variants
produced naturally in humans in order to reduce the immunogenicity.
Immunomodulation
Therapeutic interventions modulating the immune response to a
desired level rather than suppressing it. The aim is to enhance
beneficial functions while minimizing host harming processes of the
immune system.
Innate immune system
Nonspecific defense mechanisms that deliver host defense
immediately or within hours of pathogen appearance or tissue insult.
Microglia
Resident immune cells of the brain and retina that are derived from
primitive myeloid progenitors originating from the yolk sac. Microglia
cells are a long-living, autonomous, and self-renewing population and
are not replenished from postnatal hematopoietic.
Mononuclear phagocytes
Mononuclear cells include circulating blood monocytes, tissue-resident
macrophages, dendritic cells, and microglia with the ability to
phagocytose.
Non-proliferative diabetic retinopathy (non-PDR)
An early stage of diabetic retinopathy characterized by damage to
retinal vasculature and loss of pericytes. It can further progress into
PDR defined by pathological neovascular growth, vitreous hemorrhage,
retinal scars, and detachment, resulting in irreversible vision loss.
Ontogeny
All the developmental events that occur during the existence of a
living organism. In cell biology, ontogeny refers specifically to
developmental and differentiation processes within a cell lineage.
Phagoptosis (primary phagocytosis)
Cell death resulting from phagocytosis of reversibly stressed cells by
phagocytes, provoked by exposure of “eat-me” signals (e.g.,
phosphatidylserine) and/or loss of “don’t-eat-me” signals (e.g.,
polysialic acid).
Rd1 and rd10
Two of the 16 naturally occurring mouse mutant lines that manifest
degeneration of the photoreceptors. Rd1 and rd10 mice carry mutation
in exon 7 and exon 13 of the beta subunit of the rod phosphodiesterase
gene, respectively.
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(Huang et al, 2018a; Zhang et al, 2018). These repopulation mecha-
nisms are mainly regulated by the neuronal chemokine CX3CL1 and
its receptor (CX3CR1) in microglia (Zhang et al, 2018).
In the mature retina, microglia reside in the inner and outer plexi-
form layers and form a sophisticated network of non-overlapping
cells (Hume et al, 1983). Here, these cells exhibit an abundantly rami-
fied morphology spanning the complete nuclear layers with their long
protrusions (Karlstetter et al, 2015). The dynamic nature of microglia
allows them to execute housekeeping functions. The most crucial role
is the constant active surveillance of retinal homeostasis where they
are indispensable for the immune response and synaptic pruning and
transmission (Schafer et al, 2012; Wang et al, 2016a).
In order to sense the environment for endogenous or exogenous
non-physiological stimuli, microglia engage surface receptors or
pattern recognition receptors (PRRs; Kettenmann et al, 2011; Kigerl
et al, 2014). These surface receptors ligate complement compo-
nents, cytokines, chemokines, and damage- or pathogen-associated
molecular patterns (DAMPs/PAMPs; Karlstetter et al, 2015). In the
event of an insult, microglia sense the danger signals and respond
by retracting their surveilling processes concomitant with upregulat-
ing the expression of surface receptors (Jurgens & Johnson, 2012).
Furthermore, they proliferate and migrate to the site of damage,
while releasing pro-inflammatory cytokines and ROS to neutralize
the damage (Ferrer-Martin et al, 2015). Moreover, their phagocytic
capacity is significantly enhanced to effectively clear debris and
prevent accumulation of waste products (Kohno et al, 2014). In the
healthy retina, the insult is rapidly neutralized, the damaged tissue
is repaired, and a return to homeostasis is achieved with only very
little retinal remodeling (Chen et al, 2012). This finite microglial
activation is beneficial since the toxicity associated with the immune
response is outweighed by the toxicity produced due to the noxious
insult (Guillonneau et al, 2017). However, under aggravated condi-
tions owing to genetic predispositions or high glucose levels, micro-
glial activation persists (Gupta et al, 2003; Omri et al, 2011). Non-
resolving inflammation causes terminal damage since the increased
release of neurotoxic by-products and the lack of regenerative
capacity prevent retinal recovery (Chen & Xu, 2015). Furthermore,
over-reactive microglia are not able to distinguish between stressed
and apoptotic cells, and thus phagocyte viable neurons as well
(phagoptosis; Brown & Neher, 2012, 2014). Under these circum-
stances, neurotoxic microglia accumulate at the site of damage and
fail to return to their homeostatic state (Tang & Kern, 2011; Ardeljan
& Chan, 2013). Additionally, by the secretion of chemokines such as
CCL2, microglia attract further phagocytes, which include infiltrat-
ing monocytes and choroidal macrophages due to the leakage of the
BBB and the newly formed blood vessels (Caicedo et al, 2005; Senn-
laub et al, 2013). Indeed, such changes in retinal microglia morphol-
ogy, location, and infiltration of macrophages are common
hallmarks of AMD, DR, and hereditary retinopathies (Fig 1; Karlstet-
ter et al, 2015; Guillonneau et al, 2017).
Early aspects of DR consist of microaneurysms and intraretinal
microvascular anomalies (non-PDR), while PDR involves neovascu-
larization and preretinal and vitreal hemorrhages (Das et al, 2015;
Lechner et al, 2017b). Due to these clinical features, DR was only
regarded as a vascular complication; however, recent investigations
have identified inflammation as an important contributing factor in
disease development (Adamis, 2002; Rangasamy et al, 2012). Eleva-
tion in systemic and local chemokine concentration is present in
patients suffering from DR (Petrovic et al, 2010; Koleva-Georgieva
et al, 2011; Suzuki et al, 2011). Several authors could demonstrate
increased levels of TNF-a, IL-8, CCL2, IL-1b, and IL-6 in the vitreous
fluid (Demircan et al, 2006; Murugeswari et al, 2008; Boss et al,
2017). Furthermore, peripheral monocytes from DR patients secrete
high amounts of IL-1b, IL-6, TNF-a, IL-8, and IL-1ra (Hatanaka et al,
2006; Bradshaw et al, 2009). These inflammatory cytokines are asso-
ciated with phagocyte reactivity and serve as chemoattractants for
invading macrophages. Leakage of the retinal vasculature is mainly
induced by VEGF, but also involves TNF-a, which decreases the
expression of tight junction proteins ZO-1 and claudin-5 (Behl et al,
2008; Aveleira et al, 2010). The increase in endothelial cell perme-
ability then leads to further immune cell recruitment and disease
manifestation. Indeed, histopathological analysis of eyes from
patients with non-PDR and PDR exhibited increased numbers of
hypertrophic microglia which correlated with disease severity (Zeng
et al, 2008). MPs were clustered around retinal hemorrhages and
microaneurysms. In late stages, increased numbers of phagocytes
were present in the ganglion cell layer, in the newly formed blood
vessels, and around the optic nerve head (Zeng et al, 2008). Also,
there is ample evidence that hyperglycemia induces immune cell
reactivity through oxidative stress or indirectly via effects mediated
by stressed retinal cells in the proximity (Du et al, 2002; Rashid et al,
2018). Oxidative stress in hyperglycemia is driven by accelerated free
radical production concomitant with compromised antioxidant
generation (Cameron et al, 1994; Tomlinson & Gardiner, 2008).
These circumstances cause translocation of nuclear factor-kappa B
(NF-jB), pro-inflammatory cytokine expression, and MP activation
(Nishikawa et al, 2000).
Age-related macular degeneration, the leading cause of vision
loss in the elderly, is a disease of the macula–RPE–choroid interface
(Bhutto & Lutty, 2012; Ardeljan & Chan, 2013; Biesemeier et al,
2014). The RPE is essential for the maintenance and survival of
photoreceptor cells by engulfing and degrading shedded photorecep-
tor disks and protecting the retina against light and oxidative stress
(Young, 1967; Boulton, 2013; Mazzoni et al, 2014). These circum-
stances require a high metabolic activity rendering the RPE very
susceptible to oxidative damage (Mitter et al, 2012). Oxidative stress
is therefore a risk factor for AMD and hence needs rapid neutraliza-
tion to ensure proper vision (Jarrett & Boulton, 2012). Indeed, the
RPE engages in autophagy and mitophagy, directing ROS-producing
mitochondria to lysosomes, as defense mechanisms against ROS
increase (Lee et al, 2012; Mitter et al, 2012; Ferguson & Green,
2014). Mitter et al (2014) found an age-related increase in
autophagosomes and proteins involved in autophagy in the RPE;
however, these factors were significantly reduced in human AMD
donor eyes. Deteriorated autophagy concomitant with increased
accumulating ROS results in aggregation of damaged organelles and
toxic by-products including the photoreactive age-pigment lipofus-
cin (Wang et al, 2009; Mitter et al, 2014). These deposits become
apparent as drusen located in the sub-RPE area and subretinal space
during early AMD (Ishibashi et al, 1986; Abdelsalam et al, 1999;
Gupta et al, 2003; Fritsche et al, 2016). Strikingly, drusen compo-
nents include lipoproteins and complement factors serving as attrac-
tants and activators of MPs (Penfold et al, 1985; Johnson et al,
2000; Hageman et al, 2001; Nozaki et al, 2006; Buschini et al,
2011). Indeed, bloated phagocytic microglia were found to closely
associate with drusen in AMD patients (Gupta et al, 2003). While
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the elimination of retinal debris by MPs is principally positive,
impaired function during aging of these cells leads to sustained pro-
inflammatory environment (Streit et al, 2004; Chan-Ling et al, 2007;
Damani et al, 2011). A comparative transcriptome analysis of AMD
and normal human donor eyes demonstrated a significant over-
expression of immune-related transcripts including complement and
chemokine mRNAs in all AMD samples (Newman et al, 2012).
Furthermore, high levels of CCL2 and VEGF, two cytokines involved
in MP recruitment and choroidal neovascularization (CNV), are
present in ocular fluids from neovascular AMD patients (Fauser
et al, 2015; Lechner et al, 2017a). As a consequence, accumulating
subretinal microglia can directly induce death of nearby photorecep-
tors. This suggests that microglial reactivity is a driving force in
photoreceptor demise and disease manifestation.
Unlike AMD, which is a multifactorial disease, hereditary degen-
erations of the human retina are mostly monogenic. The majority of
the documented mutations are associated with genes expressed in
photoreceptors and RPE (Karlstetter et al, 2015; RetNet, 2018). RP,
the most common form of hereditary retinal degeneration, is charac-
terized by night blindness and tunnel vision due to rod demise
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Figure 1. Schematic representation of microglial activity in the retina.
Under homeostatic conditions, resident microglia mainly populate the plexiform layers. With their long protrusions, they continuously scan their environment and
phagocytose cell debris. Different insults leading to abnormal cell functions or degeneration in the RPE, the photoreceptor layer, and the ganglion cell layer rapidly alert
microglia. Resident microglia migrate to the lesion sites, where they transform into amoeboid full-blown phagocytes and recruit macrophages from the periphery. Modified
from Karlstetter et al (2010).
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(Hartong et al, 2006). Even more, late stages of RP are characterized
by central vision loss attributed to the secondary death of cone
photoreceptors (Hartong et al, 2006). Involvement of MPs was
proven by analyzing retinal sections with concentric RP demonstrat-
ing bloated microglia in the photoreceptor layer with rhodopsin-
positive inclusions (Gupta et al, 2003; Zhao et al, 2015a,b,c). The
authors hypothesized that activated phagocytes release pro-inflam-
matory cytotoxic factors that subsequently trigger the death of adja-
cent cones. The resulting pro-inflammatory environment leads to
further recruitment of MPs which, when overly activated, are
unable to discriminate between dead versus stressed-but-viable
neurons and hence engage in phagoptosis (Brown & Neher, 2012,
2014). Indeed, co-staining of rhodopsin with apoptosis markers in
mouse models of RP demonstrated rhodopsin-positive inclusions
that were mostly TUNEL-negative (Zhao et al, 2015a,b,c). Further-
more, microglial phagocytosis in the ONL corresponded to concur-
rent exposure of phosphatidylserine which serves as an “eat-me”
signal in stressed rods. Also, microglia were found to upregulate
lactadherin/milk fat globule-EGF factor 8 protein (MFG-E8), a
“bridging” molecule between phagocytes and phosphatidylserine on
neurons to facilitate rapid engulfment and internalization of stressed
neurons (Neniskyte & Brown, 2013).
Therapeutic strategies targeting mononuclear phagocytes in preclinical
models of retinal degenerative diseases
As discussed above, MP activation in the retina is initiated either
through direct recognition of immune triggers, such as DAMPs/
PAMPs, chemoattractants, and complement components, or indi-
rectly by sensing an amplitude of stressors in the surrounding envi-
ronment including ROS and “eat-me” signals from dying cells.
Overshooting MP reactivity often leads to tissue damage, but their
depletion does not always result in tissue homeostasis (Zhao et al,
2015a,b,c). Several studies point out that microglia are indispensable
for the maintenance of synaptic structures in the adult CNS. Their
depletion in the mature CNS can cause deficits in learning tasks and
a significant reduction in motor-learning-dependent synapse forma-
tion (Parkhurst et al, 2013). More importantly, phagocyte ablation in
the adult retina leads to the degeneration of photoreceptor synapses
in the outer plexiform layer and hence a functional deterioration in
retinal light responses (Wang et al, 2016a). Therefore, effective
immunomodulatory compounds should dampen the overt pro-
inflammatory response of retinal phagocytes but preserve their
homeostatic functions which are vital for retinal integrity.
Mononuclear phagocytes are composed of a heterogeneous popu-
lation with diverse functionalities (Hanisch, 2013). What remains
inconclusive is whether the beneficial and detrimental effects
carried out by reactive MPs are executed by the same population or
by distinct subtypes. Distinguishing these cell populations is a chal-
lenging task. For instance, infiltrating macrophages cannot be easily
separated from resident microglia in laser-induced CNV in mice.
Laser-induced CNV is extensively applied in retinal research since it
recapitulates several main features of exudative AMD (Lambert
et al, 2013). The laser impact results in the rupture of Bruch’s
membrane, a rapid recruitment of MPs, and penetration of choroidal
capillaries into the avascular retina within a few days. In contrast,
alternative models for experimental CNV that involve injections of
pro-angiogenic substances have a much lower incidence of neovas-
cularization (Shah et al, 2015). In order to specifically target
resident microglia and to distinguish them from short-lived infiltrat-
ing cells in this model, we used tamoxifen-inducible conditional
Cx3cr1CreER mice to delete the floxed gene for interferon-a/b recep-
tor 1 (Ifnar1; Luckoff et al, 2016). These Cx3cr1CreER:Ifnar1fl/fl mice
were subjected to laser injury 4 weeks after tamoxifen injection
when monocyte-derived macrophages were already washed out and
replaced. However, no differentiation between retinal microglia and
potentially long-lived tissue-resident macrophages in the periphery
could be achieved (Reyes et al, 2017). Another elegant approach for
cell discrimination is to use fate-mapping combined with endoge-
nous genetic reporters and multiple expression markers. O’Koren
et al (2016) demonstrated that retinal microglia have a unique CD45
(low) CD11c(low) F4/80(low) I-A/I-E() signature which is
conserved in the steady state and during retinal injury. By investi-
gating these cells, the authors found that microglia migrate to the
photoreceptor outer segments while monocyte-derived macrophages
appear throughout the entire retina (Reyes et al, 2017). For further
insights into microglia heterogeneity, the reader is directed to other
excellent reviews (Hanisch, 2013; Reyes et al, 2017).
Genetic mouse models combined with experimental approaches
mimicking retinal degenerative diseases have greatly expanded our
knowledge on the mechanisms involved in retinal MP activation
(Luckoff et al, 2017). In the following section, we present main
concepts for microglia-related immunomodulation. These strategies
involve the prevention and/or resolution of retinal degeneration and
neovascularization by (i) targeting activating and inhibitory cell
surface receptors, (ii) modulating intracellular molecules, and (iii)
controlling released inflammatory mediators.
Purinergic receptors The purines adenosine triphosphate (ATP) and
adenosine serve as neuro- and gliotransmitters in the retina
contributing to the bidirectional neuron–glia communication as well
as the cross-talk between photoreceptors and the RPE (Newman,
2006; Housley et al, 2009; Wurm et al, 2010). Physiologically, puri-
nes are tonically released in the dark; however, this release is
elevated when neurons are active (Khakh & North, 2006; Uckermann
et al, 2006; Niyadurupola et al, 2013). Growing evidence suggests
that dysregulated purinergic signaling contributes to gliosis in the
diseased retina (Sanderson et al, 2014). Degenerating cells or
elevated glucose levels increase the extracellular ATP concentration,
which activates the P2X7 receptor (P2X7R) on MPs and induces a
chemokine release through PKC/MAP kinase pathway activation
(Fig 2; Potucek et al, 2006; Costa et al, 2009; Shiratori et al, 2010;
He et al, 2017). ATP stimulation evokes the release of pro-inflamma-
tory cytokines IL-6, TNF-a, and CCL2 in primary microglia, which
was absent when P2X7 was deleted (Morigiwa et al, 2000; Shieh
et al, 2014). In a murine model of axonal injury that culminates in
the death of retinal neurons, P2X7-deficient mice exhibited a delayed
loss of retinal neurons and a decrease in phagocytic microglia
(Nadal-Nicolas et al, 2016). Moreover, intravitreal administration of
the selective P2X7 antagonist A438079 delayed axotomy-induced
ganglion cell death.
Adenosine is a neuromodulator critically involved in neurode-
generative diseases (Yu et al, 2004; Kalda et al, 2006). It modulates
microglial reactivity mainly through the activation of its G-protein-
coupled receptor A2A (A2AR; Fig 2; Cunha, 2001; Canas et al,
2009). Strikingly, agonists of A2AR potentiate LPS-induced micro-
glial reactivity (Saura et al, 2005). Conversely, its pharmacological
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inhibition results in neuroprotective effects by attenuating microglial
NO production and modulating cyclooxygenase-2 (COX2) expres-
sion in a rat model of striatal excitotoxicity (Saura et al, 2005;
Minghetti et al, 2007). Similarly, inhibition of A2AR prevents micro-
glial reactivity in mice that were subjected to intraperitoneal LPS
injection (Rebola et al, 2011) and selective A2AR blockade reduces
NO production in microglia (Madeira et al, 2015). In a retinal degen-
eration model of transient ischemia–reperfusion, intravitreal injec-
tion of the A2AR-blocking compound SCH58261 attenuated
neuronal loss by inhibiting microglial reactivity (Madeira et al,
2016). In microglia, A2AR clearly facilitates the release of cytokines
and NO production, which are likely induced through increased
cAMP levels and the activation of protein kinase A (PKA; Fig 2;
Moreau & Huber, 1999). Subsequent activation of MAP kinases
including extracellular signal-regulated kinase (ERK) 1/2 and
IkappaB kinase (IKK) then induces altered gene expression (Kyriakis
& Avruch, 2001; Schulte & Fredholm, 2003; Chio et al, 2004; Dang
et al, 2014). Recently, we showed that A2AR antagonism also limits
complement and inflammasome activation (Madeira et al, 2018).
The exposure of human microglia to RPE cell debris induced activa-
tion of the complement cascade which is strongly associated with
the pathogenesis of AMD (Zipfel & Skerka, 2009; Schick et al,
2017). Inhibition of A2AR prevented this change in microglial
complement activation as well as inflammasome activation in
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Figure 2. Activation pathways and therapy targets for mononuclear phagocytes.
(1) The purines ATP and adenosine ligate to their receptors P2X7 and A2AR, respectively, which act through PKA/PKC signaling and thereby activate IKK. IKK aids to cleave and
translocate NF-jB into the nucleus and induce inflammatory gene expression and cytokine release. A2AR additionally potentiates the expression of the complement
component C3 and the opsonin C1q. Neuroprotective effects were observed when A2AR and P2X7R were blocked using the selective inhibitors SCH58261 and A438079,
respectively. (2) Intravitreal administration of polySia avDP20 compensates for desialylated neurons by binding to its receptor SIGLEC-11 and inhibiting neurotoxic
inflammation through its ITIM domain. During inflammation, desialylated neurons activate CR3 associated ITAM and thereby trigger excessive release of ROS via NOX2. (3)
The IFN-b pathway involves STAT1- and STAT2-induced SOCS1/SOCS3 release which reduces cytokine expression through a negative feedback and inhibits IL-6 signaling. (4)
Neutralizing antibodies such as infliximab aid to neutralize cytosolic TNF-a. (5) TSPO ligands such as XBD173 stimulate the production of neurosteroids which limit the
release of pro-inflammatory cytokines. (6) Minocycline is a potent inhibitor of NF-jB signaling.
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ARPE-19 cells that were exposed to conditioned media from acti-
vated microglia treated with the A2AR blocker. Therefore, selective
A2AR antagonists could serve as tools to modulate microglial activ-
ity and limit RPE inflammatory response.
CD200 receptor CD200 is a transmembrane glycoprotein expressed
on the vascular endothelium, photoreceptors, RPE, and ganglion
cells. Its respective receptor is expressed on microglia which, upon
ligand binding, provides a potent quiescence signal (Dick et al,
2001, 2003). Deficiency in CD200 signaling is associated with micro-
glial proliferation and strong iNOS expression, indicating a latent
pro-inflammatory condition (Dick et al, 2003). In an animal model
of uveoretinitis, CD200 deficiency caused increased numbers of
microglia concomitant with increased expression of iNOS (Broderick
et al, 2002). Similarly, in the murine laser model of exudative AMD,
CD200R knockout animals displayed significantly increased new
vessel formation and elevated levels of VEGF-A, arginase 1, and IL-
1b (Horie et al, 2013). Conversely, intravitreal injection of the
CD200R agonistic monoclonal antibody DX109 diminished micro-
glial reactivity and macrophage infiltration, thereby suppressing
pathological angiogenesis and vascular damage (Horie et al, 2013).
Also, systemic administration of DX109 was effective in suppressing
IFN-c-mediated phagocyte activation and protected against tissue
damage during experimental autoimmune uveoretinitis (Copland
et al, 2007). Hence, CD200R agonists could be used to diminish pro-
angiogenic and pro-inflammatory gene expression which prevents
pathological angiogenesis.
Polysialic acid receptors In the vertebrate CNS, polysialic acid
(polySia) caps consistent of a-8-linked N-acetylneuraminic acids are
commonly attached to glycoproteins of healthy neurons (Schnaar
et al, 2014; Hildebrandt & Dityatev, 2015). PolySia can alleviate
neurotoxicity via binding to sialic acid-binding immunoglobulin-like
lectin 11 (SIGLEC-11), a primate lineage-specific receptor (Angata
et al, 2002; Linnartz-Gerlach et al, 2014). Interestingly, some strains
of neuroinvasive bacteria can also produce capsular polysaccharide
identical to polySia in order to escape immune recognition in the
human host (Troy, 1992; Schwarz et al, 2017). Ectopic expression
of human SIGLEC-11 in cultured murine microglia suppressed the
LPS-induced transcription of the pro-inflammatory mediators IL-1b
and iNOS (Wang & Neumann, 2010). SIGLEC-11 mediates immune
inhibition through its cytosolic immunoreceptor tyrosine-based inhi-
bition motif (ITIM; Fig 2). Binding of polySia to its receptor leads to
phosphorylation of ITIM (Linnartz & Neumann, 2013). Successive
recruitment of the second messenger SHP1 dephosphorylates the
intracellular immunoreceptor tyrosine-based activation motif
(ITAM), thus limiting a number of downstream pathways linked to
the phagocytosis of neurites and NADPH oxidase (NOX2)-mediated
production of ROS (Fig 2; Graham et al, 2007; Hamerman et al,
2009). Under pathological conditions, immune cells secrete neura-
minidases which cleave sialic acid residues on neurons (Amith et al,
2010; Pshezhetsky & Hinek, 2011; Nomura et al, 2017). Desialylated
neurons are consequently opsonized by complement component
C1q, which is produced and secreted by microglia (Linnartz et al,
2012; Madeira et al, 2018). Indeed, soluble sialic acid residues accu-
mulate in serum, and C1q is found in the retina during early stages
of AMD (van der Schaft et al, 1993; Goswami et al, 2003). Subse-
quently, the opsonized glycocalyx is recognized by complement
receptor 3 (CR3) coupled to ITAM leading to phagocytosis of the
neuronal structures (Fig 2; Linnartz et al, 2012). Intriguingly, block-
age of CR3 prevented neurite phagocytosis by microglia, which was
as seen when polySia was removed from cultured neurons by treat-
ment with sialidases (Wang & Neumann, 2010).
These results point toward a polySia-based therapy to target
inflammation. Consistently, studies showed that nanomolar concen-
trations of low molecular weight polySia with average degree of
polymerization of 20 (polySia avDP20) significantly reduced pro-
inflammatory gene transcription, abnormal phagocytosis, and oxida-
tive burst in human macrophages challenged with LPS or amyloid-
b1–42 (Shahraz et al, 2015). Furthermore, we used humanized
transgenic mice expressing human SIGLEC-11, subjected them to
laser injury, and treated them with intravitreal injections of polySia
avDP20 (Karlstetter et al, 2017). Already low doses of polySia
avDP20 significantly reduced microglial activation and vascular
leakage by reducing TNF-a and VEGF-A levels as well as superoxide
production (Fig 2). As a second mechanism of action, independent
from SIGLEC-11 signaling, higher doses of polySia avDP20 blocked
alternative complement activation and reduced membrane attack
formation in the diseased retina (Karlstetter et al, 2017).
Interferon-b (IFN-b) Important evidence for potent immunomodula-
tory effects of IFN-b on brain microglia came from gene deletion
studies in experimental autoimmune encephalomyelitis (EAE)
mouse models. Animals lacking either the Ifn-b gene or its cognate
interferon-a/b receptor (Ifnar) exhibited elevated microglial reactiv-
ity concomitant with an even severe EAE disease phenotype when
compared to wild-type controls (Teige et al, 2003; Prinz et al,
2008). More importantly, IFN-b treatment in a multiple sclerosis
patient completely reversed subfoveal neovascularization and
choroiditis emphasizing the therapeutic potential of IFN-b for
inflammatory and vascular diseases of the eye (Cirino et al, 2006).
We have therefore studied whether IFN-b therapy could have
beneficial immunomodulatory effects in the laser CNV model for
exudative AMD. We demonstrated that systemic administration of
IFN-b not only inhibited MP reactivity and macrophage recruitment
but also reduced vascular leakage and neoangiogenesis (Luckoff
et al, 2016). The immune cell reactivity was evaluated by counting
the total number of reactive MPs in the laser spot and their ramifi-
cation status. Both parameters were significantly affected by IFN-b
treatment. Conversely, genetic deletion of Ifnar1 in mice resulted in
aggravated disease after laser treatment. Similar results were
obtained with a microglia-specific conditional deletion of IFN-b
signaling (Cx3cr1CreER:Ifnar1fl/fl). Our results provide a mechanistic
explanation for earlier publications where damage associated with
laser photocoagulation in rabbits and monkeys was successfully
treated with IFN-b (Tobe et al, 1995; Kimoto et al, 2002). Apart
from affecting microglial reactivity by blocking the production of
neurotoxic superoxide radicals, IFN-b also promotes RPE homeosta-
sis and suppresses proliferative activity of endothelial cells (Kimoto
et al, 2002; Jin et al, 2007).
Despite the clear indications of a protective IFN-b signaling in
retinal microglia, the exact molecular pathways remain poorly
understood. IFN-b signaling involves the transcription of suppressor
of cytokine signaling 1 (SOCS1) and SOCS3 by translocating the tran-
scription factors STAT1 and STAT2 into the nucleus (Rashid et al,
2018; Fig 2). SOCS1 and SOCS3 expression is known to engage in
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inhibitory signals to mitigate microglial activation and prevent cell
toxicity (Kimura et al, 2005; Baker et al, 2009; McCormick & Heller,
2015). Supporting evidence comes from a study where SOCS3 defi-
ciency in myeloid cells exaggerated retinal degeneration and acceler-
ated retinal angiogenesis in a murine model of uveoretinitis (Chen
et al, 2018). In these mice, SOCS3-deficient retinas demonstrated
higher levels of pro-inflammatory cytokines IL-1b, TNF-a, and IFN-c
as well as angiogenic factors including VEGF-A. Similarly, SOCS1
protected retinal cells from staurosporine- and H2O2-induced apopto-
sis (Yu et al, 2011). Also, members of the SOCS family are poten-
tially key physiological negative regulators of IL-6 signaling in
macrophages (Croker et al, 2003; Wilson, 2014; Fig 2).
TSPO ligands Translocator protein 18 kDa (TSPO) is a highly
conserved 5a-helical transmembrane protein located on the outer
mitochondrial membrane (Girard et al, 2012). Highly induced TSPO
protein expression is predominantly found in activated microglia
during various neuropathological conditions (Daugherty et al, 2013;
Karlstetter et al, 2014; Rashid et al, 2018). Concomitantly, astro-
cytes and Mu¨ller cells upregulate the secretion of an endogenous
TSPO ligand, diazepam binding inhibitor (DBI) protein which is
sensed by microglia and serves to limit the magnitude of microglial
reactivity by inducing feedback regulation (Wang et al, 2014).
Finally, triakontatetraneuropeptide (TTN), the biologically active
cleavage product of DBI, triggers the transformation of activated
microglia to baseline quiescence (Wang et al, 2014).
Based on this concept of feedback regulation, synthetic TSPO
ligands were effective immunoregulators in various animal models
for neurological diseases including Alzheimer’s disease, multiple
sclerosis, and anxiety disorders (Rupprecht et al, 2009; Barron et al,
2013). In our study on retinal degeneration, we tested the ability of
the specific TSPO ligand XBD173 to dampen microglial reactivity in
the acutely white light-damaged mouse retina (Fig 2). In this model,
exposure to intense white light leads to a significant loss of photore-
ceptor cells and thinning of the outer nuclear layer within a few
days after dark adaptation and light exposure (Wenzel et al, 2005).
We found that systemic administration of XBD173 markedly limited
the accumulation of amoeboid microglia in the outer retina and
protected from overt cell death (Scholz et al, 2015a). Mechanisti-
cally, XBD173 efficiently suppressed pro-inflammatory gene expres-
sion in cultured microglia and reduced neuronal cell death in
microglia-conditioned medium (Karlstetter et al, 2014). Moreover,
XBD173 triggered a neuroprotective microglia phenotype in
explanted organotypic mouse retinal cultures (Karlstetter et al,
2014). These effects mediated by XBD173 were prevented upon
blocking the enzymatic conversion of cholesterol to pregnenolone
(Fig 2), which can be converted to progesterone, a potent neuros-
teroid with pleiotropic neuroprotective properties (Pettus et al,
2005; Guennoun et al, 2015; Cai et al, 2018). In rd1 mice, a model
for retinitis pigmentosa, oral progesterone treatment decreased glio-
sis and cell death leading to improved retinal function (Sanchez-
Vallejo et al, 2015). Similarly, TTN stimulation of microglia
increased levels of dehydroepiandrosterone, an effective anti-inflam-
matory neurosteroid (Wang et al, 2014), and the TSPO ligand Ro5-
4864 effectively reduced diabetic neuropathy through a local
increase in neurosteroids (Giatti et al, 2009). These findings clearly
support the concept that TSPO exerts its neuroprotective effects by
modulating neuronal steroidogenesis.
Minocycline Minocycline is a membrane-permeable semi-synthetic
tetracycline derivative with strong neuroprotective and
immunomodulatory effects (Garrido-Mesa et al, 2013). Minocycline
blocks microglial activation in response to a variety of inflammatory
stimuli by inhibiting Toll-like receptor 2 (TLR2) and TLR4 signaling
(Nikodemova et al, 2006; Halder et al, 2013). TLRs induce a potent
immune response upon recognition of PAMPs (Uematsu & Akira,
2006). Receptor signaling triggers cytokine production through
translocation of NF-jB into the nucleus which is essential for the
defense of the host cell (Beutler, 2004). Increased expression of
TLR2 and TLR4 concomitant with elevated NF-jB levels is often
found in human monocytes under conditions of hyperglycemia
(Mohammad et al, 2006; Dasu et al, 2008). In the mouse retina,
pre-diabetic conditions and high-fat diet caused TLR4-dependent
activation of microglia ad macrophages concomitant with vision
loss (Lee et al, 2015). Microglia themselves can experience necrop-
tosis, a form of inflammatory cell death, through TLR4 activation in
rd1 mice, thereby exacerbating retinal inflammation and damage
(Huang et al, 2017).
Minocycline potently inhibits NF-jB transcriptional activity by
blocking the degradation of IjBa (Nikodemova et al, 2006; Fig 2).
Systemic minocycline therapy in light-damaged mice reduced pro-
inflammatory cytokine release, prevented microgliosis, and
preserved photoreceptor function in the retina (Zhang et al, 2004;
Scholz et al, 2015b). Similarly, minocycline inhibited microglial
reactivity and photoreceptor apoptosis in the rd10 mouse model of
human RP (Peng et al, 2014). In a streptozotocin (STZ)-induced rat
model of DR, minocycline blocked microglial COX2 expression and
prevented the release of IL-1b and TNF-a with concomitant reduc-
tion in caspase-3-mediated apoptosis (Krady et al, 2005). Recent
evidence also suggests that minocycline can block the expression of
PARP1, a chromatin-associated enzyme which promotes the expres-
sion of IL-1b and TNF-a in glial cells, and thereby reduces retinal
apoptosis (Wu et al, 2015).
Cytokine inhibition Enhanced levels of pro-inflammatory cytokines
are involved in AMD (de Oliveira Dias et al, 2011), RP (He et al,
2015), and DR (Patel et al, 2008). Specifically, the cytokines TNF-a,
IL-1b, and IL-6 are significantly elevated in retinal pathologies at the
time point of immune cell reactivity (Armstrong et al, 1998; Oh
et al, 1999; Seddon et al, 2005; Poon et al, 2015; Zhao et al, 2015a).
Therefore, scavenging of cytokines has been a valid therapeutic
concept in these retinal pathologies.
Several TNF-a-inhibiting antibodies have been developed and
tested as potential therapy options for retinal degenerations includ-
ing preclinical models for AMD, glaucoma, and ischemic retinopa-
thy (Al-Gayyar & Elsherbiny, 2013). Secretion of TNF-a by
phagocytes stimulates VEGF production in RPE and promotes angio-
genesis, hence being a candidate target for treating AMD and DR
(Cousins et al, 2004; Regatieri et al, 2009). TNF-a is also a negative
regulator of the RPE transcription factor orthodenticle homeobox 2
(OTX2) which orchestrates expression of critical genes involved in
proper retinal function (Mathis et al, 2017). In various rodent
models, researchers demonstrated positive effects of intravitreal
injections of the TNF-a antibodies (Shi et al, 2006; Regatieri et al,
2009). Histopathological findings confirmed that CNV lesions in
treated mice were smaller in size compared to the control animals
(Shi et al, 2006). Furthermore, intravitreal injection of low doses of
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infliximab (10–40 lg) abates the cytokine availability and modu-
lates angiogenesis (Fig 2; Regatieri et al, 2009). Studies in monkey
demonstrated that intravitreal injections of adalimumab and the
single-chain antibody fragment ESBA105, both potent TNF-a inhibi-
tors, resulted in CNV reduction, whereas topical treatment had only
weak effects (Lichtlen et al, 2010).
IL-1b is strongly involved in neovascularization by triggering the
release of angiogenic factors (Joyal et al, 2011; Horie et al, 2013;
Rivera et al, 2013). Thus, IL-1b induces a robust release of
semaphoring-3A in retinal ganglion cells and RPE in an oxygen-
induced retinopathy model (Martin et al, 2004; Joyal et al, 2011).
Sema3A critically contributes to vascular decay and misguided
revascularization (Rivera et al, 2013). Furthermore, excessive IL-1b
release induces P2X7R expression on monocytes, thereby triggering
further IL-1b release and retinal apoptosis (Giuliani et al, 2017).
Inhibition of IL-1b or P2X7R completely prevented the inflamma-
tion-associated photoreceptor demise (Hu et al, 2015). Recently,
Natoli et al (2017) showed that inhibition of retinal IL-1b reduced
phagocyte accumulation and photoreceptor death via downregulat-
ing chemokine expression by Mu¨ller cells and RPE in rats with focal
photo-oxidative damage.
Likewise, high levels of IL-6 are significantly related to AMD
progression and increased in mice with experimentally induced
CNV (Seddon et al, 2005; Izumi-Nagai et al, 2007). Systemic admin-
istration of the anti-IL-6R monoclonal antibody MR16-1 effectively
suppressed the expression of CCL2 and VEGF and reduced macro-
phage infiltration as well as the CNV area (Izumi-Nagai et al, 2007).
IL-6 is known to repress Fas ligand expression in the RPE, which
then leads to impaired clearance and accumulation of MPs in the
subretinal space (Levy et al, 2015).
Chemokine modulation Fractalkine or CX3CL1 is a neuronal chemo-
kine which binds to its receptor CX3CR1 on microglia and macro-
phages (Geissmann et al, 2003; Wolf et al, 2013). The tightly
regulated cross-talk between neurons and microglia involving
CX3CL1–CX3CR1 has an important role in immunoregulation and
neuroprotection in the brain and the retina (Wolf et al, 2013; Zieger
et al, 2014). Thus, CX3CR1-deficient mice show a higher susceptibility
to subthreshold light challenge leading to the accumulation of subreti-
nal microglia, which can be prevented by keeping the animals in the
dark (Combadie`re et al, 2007; Chinnery et al, 2012). Inhibition of CC-
motif chemokine ligand 2 (CCL2) or IL-1b also prevented inflamma-
tory macrophage recruitment and photoreceptor degeneration in these
animals (Sennlaub et al, 2013; Eandi et al, 2016). Conversely, positive
modulation of CX3CL1–CX3CR1 signaling in the diabetic mouse retina
by intravitreal administration of recombinant fractalkine effectively
reduced microglial proliferation (Mendiola et al, 2017).
The otherwise low expression of CCL2 in the retina is strongly
enhanced under stressful conditions (Nakazawa et al, 2007; Chen
et al, 2012). It is primarily secreted by activated microglia to recruit
inflammatory monocytes expressing CCR2 (Mizutani et al, 2012;
Sennlaub et al, 2013). The pro-inflammatory CCL2/CCR2 axis repre-
sents a valid target for inhibition to restore immune balance. Thus,
rats receiving intravitreal injection of CCL2 siRNA showed a mark-
edly decreased phagocyte accumulation and photoreceptor apopto-
sis after light damage (Rutar et al, 2012). Similarly, CCR2 knockout
mice had much lower photoreceptor demise after chronic blue light
exposure (Hu et al, 2016), less pro-inflammatory cells and CNV in
the laser-damage model (Robbie et al, 2016), and fewer subretinal
macrophages when immunized with carboxyethylpyrrole-modified
albumin as trigger for oxidative stress (Cruz-Guilloty et al, 2013).
The secretion of CCL3 by microglia is an early event in the
pathologies of the Abca4/ Rdh8/ mouse model of Stargardt
disease and the Mertk/ mouse model of RP (Kohno et al, 2014).
Consequently, knockout of CCL3 in these mice resulted in a milder
disease form with increased retinal thickness, fewer numbers of
subretinal phagocytes, and marked reduction in vascular leakage
(Kohno et al, 2014).
Mononuclear phagocyte-targeted therapy in patients with retinal
pathologies
Hyper-reflective foci When monitoring the retina of wet AMD
patients using spectral domain optical coherence tomography (SD-
OCT), small, dense particles—thereby referred to as hyper-reflective
foci (HF)—were identified (Framme et al, 2010; Altay et al, 2016).
Similarly, HF were found in eyes of patients with different stages of
diabetic retinopathy (De Benedetto et al, 2015; Korot et al, 2016),
and a positive correlation between HF number, hard exudate size,
disease severity, and inflammation has been recognized (Bolz et al,
2009; Lammer et al, 2014; Niu et al, 2017). Interestingly, the appear-
ance and resolution of HF can be used to complement current diag-
nostic tools and predict disease progression and therapeutic success
(Gallagher et al, 2007; Coscas et al, 2013; Abri Aghdam et al, 2015).
These findings led to the assumption that HF may represent either
migrating RPE cells or reactive and bloated immune cells (Framme
et al, 2010; Christenbury et al, 2013; Coscas et al, 2013; Gocho et al,
2013). Pang et al compared HF with histological analyses in two
donor eyes and found cholesterol crystals, indicating that HF are
either RPE cells or lipid-filled phagocytes (Ogino et al, 2012; Pang
et al, 2015). Thus, the success of phagocyte-targeting therapies could
be potentially assessed by monitoring the presence and number of
retinal HF using non-invasive OCT imaging.
Clinical trials Despite the very promising results in a wide range of
preclinical studies targeting retinal phagocytes, only limited data are
available from clinical trials. In a phase I/II study, Nussenblatt et al
compared three immunosuppressive agents—daclizumab, rapa-
mycin, and infliximab—in combination with anti-VEGF therapy in
AMD patients (Nussenblatt et al, 2010). The authors found that
treatment with the anti-IL-2 receptor antibody daclizumab, as well
as the mTOR inhibitor sirolimus, but not infliximab, decreased the
number of anti-VEGF intravitreal injections. However, no significant
changes in visual acuity were evident. In contrast, other studies
reported positive effects on vision gain following intravitreal or
systemic infliximab treatment in patients with AMD and DR
(Sfikakis et al, 2005, 2010; Theodossiadis et al, 2009) although
some retinotoxicity was found in a small group of patients (Giganti
et al, 2010).
Oral minocycline treatment was tested in five patients with DME
and one patient with RP (Cukras et al, 2012; Baumgartner & Baum-
gartner, 2013). A 6-month treatment with minocycline improved
visual function, central macular edema, and vascular leakage in the
DME patients (Cukras et al, 2012). The RP patient received minocy-
cline together with the anti-apoptotic drug deprenyl for 120 months
and showed a slower decline in visual field as estimated from the
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previously documented disease course (Baumgartner & Baumgart-
ner, 2013).
Targeting the complement system in retinal
degenerative diseases
The complement pathways
The complement system, with over 30 small proteins, is a crucial
component of innate immunity. Its origins can be traced back to a
billion years ago when primitive proteins evolved to protect cells from
pathogens. However, it was only discovered around 125 years ago as a
liver-derived heat-labile substance circulating in the blood that “comple-
ments” antibodies in lytic killing of bacteria, fungi, and viruses.
The system becomes activated in a cascade fashion when trig-
gered through one or more of the three major pathways: the classi-
cal pathway (CP), the mannose-binding lectin (MBL) pathway, and
the alternative pathway (AP; Fig 3). There are two critical steps for
the full activation of the complement pathways: C3 cleavage and C5
cleavage by relevant convertases (Fig 3).
These convertases generate (i) C3b that may participate in
opsonizing pathogens or dead cells and promoting their clearance,
or form C5 convertase in the AP’s feedback loop (Fig 3), (ii) C3a
and C5a that can induce vasodilation, increase the permeability of
small blood vessels, and induce contraction of smooth muscles
(Fig 3), and (iii) C5b-C9, also called membrane attack complex
(MAC) that can modulate the immune response or affect cell cycle
when released as a soluble form and at sublytic levels (Lueck et al,
2011; Lakkaraju et al, 2014) or form transmembrane channels on
cell surfaces causing lysis (Fig 3).
Activation of the complement system is tightly controlled by a
group of soluble and membrane-bound regulators, including (i) C1-
inhibitor (C1INH) that inactivates C1r and C1s or MASP1 and
MASP2 proteases and prevents CP- and MBL-mediated complement
activation, (ii) factors that accelerate the decay of convertases, such
as the membrane-bound CD55 or fluid phase factor H (CFH), and
the transmembrane CD46, and (iii) CD59 that blocks the MAC
assembly (Morgan & Wong et al, 1995; Zipfel & Skerka, 2009;
Schmidt et al, 2016; Fig 3).
Although the main source of circulating complement components
is the liver, complement proteins, receptors, and regulators are also
produced and expressed locally by other cells, including immune
cells and various tissue cells (Heeger & Kemper, 2012; Kolev, 2014).
Locally produced complements are known to play an important role
in tissue homeostasis, and thus, dysfunction or dysregulation of the
system may contribute to various diseases. Recent studies have
shown that the complement system can also be activated inside the
cell, and intracellular complement activation is known to be
involved in many important cellular functions, including intracellu-
lar pathogen recognition/elimination, cytokine production, and
metabolism (Arbore et al, 2017; Kolev & Kemper, 2017; Liszewski
et al, 2017).
Complement regulation in the retina
As an immune privileged tissue, the retina is segregated from
systemic circulation by various barriers (e.g., BRBs), and circulating
complement proteins are not able to freely move into the retinal
parenchyma under physiological conditions. However, the retina
itself produces a variety of complement proteins, receptors, and
regulators (Anderson et al, 2010). For example, transcripts of C1qb,
C1r, C2, C3, C4, CFB, and CFH were detected in the retina and RPE/
choroid of human (Anderson et al, 2010) and mouse eyes (Luo
et al, 2011). Complement regulatory proteins such as CD46 (Vogt
et al, 2006; Fett et al, 2012), CD55 and CD59 (Vogt et al, 2006), and
CFH (Chen et al, 2007) as well as complement receptors CR1 and
C3aR (Fett et al, 2012) and C5aR (Vogt et al, 2006) were found in
retinal neurons and RPE cells.
Complement genes in the retina (Chen et al, 2010) and RPE/
choroid (Chen et al, 2008) are expressed in an age-dependent fash-
ion. Also, the expression of C3, C4, and CFB in mouse retina can be
affected by cataract surgery (Xu et al, 2011) and irradiation (Chen
et al, 2012). Recently, an age-related accumulation of MAC was
found in the choriocapillaris of healthy donor eyes (Mullins et al,
2014; Chirco et al, 2016). The role of complement proteins in retinal
cell homeostasis and activation remains to be fully elucidated, and
this should be an important point of consideration when targeting
the complement system for treating retinal diseases.
The role of the complement system in retinal degeneration
The underlying pathologies of DR are retinal microvascular
damage and neuronal degeneration. C3d and C5b-9 have been
detected in the choriocapillaris of DR eyes (Gerl et al, 2002) as
well as in retinal vessels of patients suffering from type 2 diabetes
for more than 9 years (Zhang et al, 2002), suggesting that the
complement system may damage vascular endothelial cells
through C5b-9-mediated lytic killing in diabetic eyes. In addition,
uncontrolled complement activation may also contribute to peri-
cyte loss in DR. Retinal pericyte-reactive autoantibodies have been
detected in patients with DR (Zhang et al, 2016) and in vitro stud-
ies have shown that the autoantibody-initiated complement activa-
tion can induce pericyte damage and loss of function (Li et al,
2012). Increased C3a and C5a were detected in the serum (Zhang
et al, 2016) and vitreous of patients with PDR (Muramatsu et al,
2013). C3a- and C5a-induced inflammation may also contribute to
DR pathogenesis. For example, Mu¨ller cells constitutively express
C5aR and the expression can be upregulated by hyperglycemia and
inflammatory stimuli such as prostaglandin E, which then results
in the release of IL-6 and VEGF, both known to be critically
involved in DR pathology (Cheng et al, 2013).
The role of the complement system in the pathogenesis of AMD
has been studied and reviewed extensively over the past decade
(Warwick et al, 2014; Bora et al, 2015; McHarg et al, 2015). Key
facts supporting the role of the complement system in the pathogen-
esis of AMD include the following: (i) Several complement compo-
nents have been detected in drusen and AMD lesions (Anderson
et al, 2002, 2010); (ii) higher plasma levels of C3a, C3d, Bb, and
C5a have been observed in AMD patients (Scholl et al, 2008;
Reynolds et al, 2009; Lechner et al, 2016); (iii) polymorphisms in a
number of complement genes (CFH, CFB, C2, SERPING1, and C3)
are genetic risk factors of AMD (Edwards, 2008; Cipriani et al,
2012); and (iv) inhibition of complement suppresses laser-induced
CNV in mice (Nozaki et al, 2006; Bora et al, 2010; Kim et al, 2013;
Lipo et al, 2013). Mechanistically, CFH may inhibit CD47-mediated
resolution of subretinal inflammation and this inhibitory effect
could be enhanced by the AMD associated CFH (H402) variant
(Calippe et al, 2017).
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A recent transcriptome study of two advanced stages of RP in
dogs showed strongly increased gene expression of inflammasome
and complement factors in the retina (Sudharsan et al, 2017).
However, earlier studies reported reduced C3 and C4 levels and
increased immune complexes in the sera from RP patients, and this
reduced systemic complement activity appears to be related to poor
disease prognosis (Heredia et al, 1984). The rhodopsin T17M muta-
tion also reduces C3 secretion in RPE cells (Xiong et al, 2017),
suggesting that some RP-related genes may regulate complement
expression/secretion by RPE cells. Humphries et al showed that
C1q, the primary component of the classical pathway of the comple-
ment system, is a survival factor for cone cells, and C1q deficiency
promoted photoreceptor death in Rho/ mice, a mouse model of
Leber’s congenital amaurosis (LCA; Humphries et al, 2012). Further
understanding the role of complement system activation in RP may
uncover novel targets for therapy.
Modulating the complement system for the management of retinal
degenerative diseases
Despite extensive research and significant advances in understand-
ing the role of the complement system in retinal health and disease,
the therapeutic value of these findings has only been tested in small
groups of selected patients, such as the GA type of AMD (see
below). A number of reasons may explain the slow progression in
translations. First, complement dysregulation is not the primary
cause of disease. The complement system only comes into play
when retinal damage is evident. Therefore, modulating the comple-
ment system without addressing the initial cause of the disease may
have limited impact on disease progression. Second, the physiologi-
cal purpose of complement activation is likely to limit retinal
damage and promote repair although excessive C3a, C5a, and C5b-
C9 may be detrimental. It is, therefore, critical to differentiate the
beneficial roles from the detrimental roles of complement activation
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Figure 3. Complement activation, regulation, and immune functions.
(A) The complement system can be activated by three pathways: the classical pathway (CP), mannose-binding lectin (MBL) pathway, and the alternative pathway (AP);
all lead to the cleavage of C3 and C5 and the formation of C5b-C9. In the CP and MBL pathways, the C3 and C5 convertases are C4b2a and C4b2a3b, whereas in the
AP, they are C3bBb and C3bBbC3b, respectively. Once C3 is cleaved into C3a and C3b, the C3b fragment can form C3bBb to amplify the complement activation
cascade. Therefore, even if the initial activation is mediated by CP or MBL pathway, the cascade is ultimately amplified by the AP. (B) The complement activation
cascades are regulated at multiple levels. Properdin is the only factor that stabilizes C3bBb and enhances complement activation. CFI, CD46, CFH, CR1, and C4BP
prevent the assembly of C3 and C5 convertases by further breaking down C3b and C4b, whereas CD55, CR1, CFH, and C4BP can dissociate C3 and C5 convertases.
CD59 and S protein can prevent the assembly of C5b-C9. (C) Activation of the complement system generates C3a, C3b, and C5a fragments that are actively involved in
immune responses. The soluble form of and sublytic levels of C5b-C9 can regulate immune cell functions, whereas the membrane MACs directly kill pathogens and
cells.
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in retinal degeneration. Third, complement proteins and regulators
may modulate retinal disease independent from the complement
cascades. Complement-based therapies are at different stages of clin-
ical development for retinal diseases, particularly AMD (Xu & Chen,
2016).
Early clinical trials have proven that complement inhibitors are
generally safe and well tolerated when injected intravitreally. The
phase II/III studies have been conducted predominately in GA
patients. For example, the latest C3-targeted inhibitor APL-2 has
shown promising effect in the phase II study (NCT02503332),
which reported a 29% reduction in the rate of GA lesion growth
and 20% reduction in the group that received APL-2 injection
every other month. A greater effect was observed during the
second 6 months of the study where a reduction in GA growth
rate of 47 and 33% was seen in patients with monthly and every
other month treatment, respectively. The phase III study is
planned to begin in the second half of 2018 (Apellis-Pharmaceuti-
cals, 2018).
Lampalizumab (FCFD4514S) is a humanized IgG Fab fragment
against CFD, thereby reducing the activation of the alternative
complement pathway (Katschke et al, 2012). A phase II study
(MAHALO) reported a 20% reduction in lesion area progression
compared with sham control after 18-month treatment of monthly
intravitreal injections. Further subgroup analysis revealed a 44%
reduction in patients who carry the CFI risk allele (rs17440077;
Yaspan et al, 2017). However, further phase III studies (Spectri,
NCT02247531; and Chroma, NCT02247479) failed to confirm the
therapeutic effect in GA patients.
CLG561 is a fully humanized anti-properdin antibody Fab frag-
ment. Properdin promotes the association of C3b with CFB and
provides a focal point for the assembly of C3 convertase C3bBb. A
phase II study evaluating the safety and efficacy of intravitreal injec-
tions of CLG561 as a monotherapy and in combination with LFG316
in GA patients is ongoing (NCT02515942).
It must be noted that several other complement trials have ended
early due to disappointing interim results. This highlights our lack
of basic understanding of the mechanisms by which complement
factors influence AMD. Thus, we are currently unable to address
precisely when, where, and how to modulate the complement path-
way in AMD and other retinal degenerative conditions.
Targeting inflammasome activation in retinal
degenerative diseases
The inflammasome signaling pathway
The inflammasomes are cytosolic macromolecular signaling
complexes that mediate IL-1b and IL-18 secretion the lytic cell death
called pyroptosis. They play a crucial role in innate immunity by
coordinating host immune response to invading pathogens or host-
derived danger signals. Assembly of inflammasomes is triggered by
different PRRs, including nucleotide-binding oligomerization
domain-like receptors (NLRs), absent in melanoma 2 (AIM2)-like
receptors (ALRs), or tripartite motif (TRIM) family receptors, which
are capable of recognizing PAMPs and DAMPs. Assembly of the
inflammasomes allows for the cleavage and activation of inflamma-
tory caspases, which in turn cleave pro-inflammatory cytokines pro-
IL-1b and pro-IL-18 into their active forms.
Since NLRP1 was first described to form the inflammasome in
2002 (Martinon et al, 2002), members of the NLR family (NLRP1,
NLRP3, and NLRC4) as well as other proteins (AIM2, pyrin) have
been confirmed to initiate formation of inflammasomes (Broz &
Dixit, 2016; Mathur et al, 2017). There are also other less well-char-
acterized PRRs, such as NLRP2, NLRP6, NLRP7, NLRP9b, NLRP12,
IFN-c-inducible protein 16 (IFI16), and retinoic acid-inducible gene I
(RIG-I; also known as DDX58) which have also been reported to
activate caspase-1 (Broz & Monack, 2013; von Moltke et al, 2013;
Broz & Dixit, 2016; Man & Kanneganti, 2016).
To date, the best studied and well-characterized NLR molecule is
NLRP3 (also known as NALP3, cryopyrin, CIAS1, and Pypaf1).
Assembly of NLRP3 requires two signals: (i) a priming signal which
activates NF-kB, subsequently promoting the transcription of NLRP3
and pro-IL-1b, and (ii) an activation signal which facilitates the
oligomerization of NLRP3, ASC, and procaspase-1, resulting in the
activation of NLRP3 inflammasome and secretion of mature IL-1b
and IL-18 (Fig 4; Bauernfeind et al, 2009; Franchi et al, 2012, 2014;
Juliana et al, 2012). In addition to the canonical inflammasomes, the
non-canonical inflammasome signaling pathways also exist, which
target caspase-11 in mice and caspase-4 and caspase-5 in humans. Shi
et al (2014) have shown that caspase-4/5/11 can directly respond to
cytoplasmic LPS leading to self-oligomerization and activation.
Clinical data on involvement of inflammasome in retinal diseases
Aberrant inflammasome activation has been implicated in multiple
diseases, including retinal diseases. For instance, Tarallo et al (2012)
displayed that NLRP3, IL-1b, and IL-18 mRNA abundance in the RPE
from human eyes with GA was markedly elevated compared to
normal age-matched control eyes. Others also observed upregulation
of NLRP3, pro-IL-1b, and pro-IL-18 mRNA in the macula of both GA
and nAMD (Cao et al, 2016; Wang et al, 2016b). Zhao et al (2015a)
analyzed the protein level of pro-IL-1b and IL-1b in vitreous samples
from patients with retinal diseases. The results show that pro-IL-1b
levels in nAMD, polypoidal choroidal vasculopathy (PCV), and
Eales’ disease vitreous samples were significantly elevated, and IL-
1b expression in nAMD, PCV, Eales’ disease, and RVO vitreous
samples was significantly elevated when compared with the control
group. Interestingly, IL-1b levels in serum samples of PCV and
nAMD were significantly decreased in the same study.
Inflammation is assumed to be involved in the generation of
neovascularization in PDR (Zhou et al, 2012). Most recently, Louko-
vaara et al (2017) reported that NLRP3 inflammasome activation is
associated with the pathogenesis of PDR. It is also demonstrated that
high intraocular pressure (IOP)-induced retinal ischemia could trigger
caspase-8 signaling to activate NLRP1 and NLRP3 inflammasomes
and IL-1b secretion via TLR4 signaling in both mouse and rat models
(Chi et al, 2014). These results provide new insights into the patho-
genesis and development of new therapeutic strategies for clinical
treatment by linking NLRP3 inflammasome and retinal diseases.
Triggers of inflammasome activation in the retina
Oxidative stress Increasing evidence suggests that ROS induces the
activation of NLRP3 inflammasome and enhances the secretion of
IL-1b (Zhang et al, 2015; Choe & Kim, 2017). In STZ-induced
diabetic mice, rod demise was accompanied by an increase in LC3A
protein, a marker for autophagosomes (Mizushima & Yoshimori,
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2007; Piano et al, 2016). Similarly, ARPE-19 cells showed signs of
autophagy together with ROS release in response to high-glucose-
induced stress (Shi et al, 2015). Inhibition of the autophagic
response activated even more NLRP3 and caused IL-1b release. The
authors speculate that the cells incapable of removing ROS-gener-
ating mitochondria may trigger NLRP3 inflammasome activation
(Youle & Narendra, 2010; Shi et al, 2015). Thus, NLRP3 inflamma-
some activity is stimulated by ROS accumulation and counter-
balanced by autophagy (Zhou et al, 2010b).
Retinal lipofuscin contains lipid peroxidation- or glycoxidation-
induced end products 4-hydroxynonenal (HNE), malondialdehyde
(MDA), and advanced glycation end products (AGEs; Schutt et al,
2003). Kauppinen et al (2012) reported that HNE induced signifi-
cantly increased NLRP3 mRNA levels and IL-1b and IL-18 produc-
tion in RPE cells.
Thioredoxin (TRX)-interacting protein (TXNIP), a TRX-binding
protein, is thought to be an endogenous inhibitor of TRX reductase
activity. TXNIP dissociates from TRX at high concentrations of H2O2
and interacts with NLRP3. ROS-dependent TXNIP–NLRP3 associa-
tion was also found in monosodium urate crystals or R-837-treated
macrophages (Zhou et al, 2010a). TXNIP can also mediate retinal
inflammation, gliosis, and apoptosis in experimental diabetes (Devi
et al, 2012). Zhou et al demonstrated a vital role of TXNIP in innate
immunity through NLRP3 inflammasome activation and release of
IL-1b under oxidative stress. Recent studies demonstrated that ROS–
TXNIP pathway mediates NLRP3 inflammasome activation in DR
conditions in vitro and in vivo in rats. High glucose induces
sustained upregulation of TXNIP, ROS generation, and inflammation
in a Mu¨ller cell line of rats, and antioxidants or TXNIP silencing
blocked IL-1b and IL-18 secretion in high-glucose-exposed human
retinal microvascular endothelial cells (Devi et al, 2012; Chen et al,
2017). These results provide a potential therapeutic target for the
treatment of DR.
Lysosomal membrane permeabilization Lysosomal membrane
permeabilization (LMP) is a key mechanism upstream of NLRP3
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Figure 4. Molecular mechanisms of NLRP3 inflammasome priming and activation.
Schematic representation of the NLRP3 inflammasome pathway which requires two signals: (i) a priming signal which activates NF-kB, subsequently promoting the
transcription of NLRP3 and pro-IL-1b, and (ii) an activation signal which facilitates the oligomerization of NLRP3, ASC, and procaspase-1, resulting in the activation of NLRP3
inflammasome and secretion of mature IL-1b and IL-18.
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inflammasome activation, which induces subsequent cytosolic leak-
age of lysosomal components (Hornung et al, 2008; Stutz et al,
2009). Lysosome rupture triggers various cellular responses, includ-
ing NLRP3 inflammasome activation, autophagy, and cell death
(Okada et al, 2014). As lysosomes are organelles containing abun-
dant amount of Ca2+, lysosome rupture induces Ca2+ influx from
the lysosome into the cytosol activating the NLRP3 inflammasome
through the CaMKII–TAK1–JNK pathway (Okada et al, 2014). TAK1
and JNK are activated in response to a soluble lysosomotropic agent
L-leucyl-L-leucine methyl ester (LLME) stimulus, and inhibitors of
cathepsin B, cysteine proteases, or 5-Z-oxozeaenol (a TAK1 inhi-
bitor) strongly attenuate the LLME-induced activation of JNK. JNK
is a family member of MAPK that responds to stress and that can
regulate the activation of the NLPR3 inflammasome through ASC
oligomerization. Furthermore, various LMP stimuli trigger signifi-
cant K+ efflux (Munoz-Planillo et al, 2013). Katsnelson et al (2015)
reported that Ca2+ influx and K+ efflux are rapidly triggered after
murine dendritic cell treatment with LLME. The lipofuscin compo-
nent N-retinylidene-N-retinyl-ethanolamine (A2E) was also shown
to trigger LMP (Taylor et al, 1992; Tomany et al, 2004). Brandstetter
et al found that lipofuscin-mediated phototoxicity results in LMP
with cytosolic leakage of lysosomal enzymes and subsequent activa-
tion of caspase-1 and inflammasome with secretion of IL-1b and IL-
18 in RPE cells. NLRP3 inflammasome activation induced by LMP
may contribute to AMD pathology through the release of pro-inflam-
matory cytokines such as IL-1b as well as through caspase-1-
mediated pyroptosis (Tseng et al, 2013; Brandstetter et al, 2015b).
ATP and P2X7 receptor P2X7R chiefly acts through the recruitment
of the NLRP3 inflammasome complex (Giuliani et al, 2017). As a
known and powerful activator of the NLRP3, P2X7R modulates
NLRP3 expression at mRNA and protein levels, and excessive acti-
vation results in RPE cell death (Franceschini et al, 2015). During
P2X7R opening, it directly allows K+ efflux and Ca2+ influx along
the concentration gradient. K+ efflux is now acknowledged as a
very potent stimulus for caspase-1 activation and pro-IL-1b release
that activates the NLRP3 inflammasome (Franchi et al, 2007;
Petrilli et al, 2007; Franceschini et al, 2015). Recent evidences
suggest that P2X7R and NLRP3 interact directly at discrete sub-
plasmalemmal cytoplasmic sites. P2X7R and NLRP3 can be co-
localized by confocal microscopy and co-immunoprecipitated in
both mouse microglia and mouse peritoneal macrophages
(Franceschini et al, 2015).
Adenosine triphosphate promotes caspase-1 activation, NLRP3
activation, IL-1b and IL-18 maturation and release, and cell death
(Ferrari et al, 1997a; Perregaux et al, 2000). RPE cells and neural
retina have been shown to release ATP in response to stimulation
(Neal & Cunningham, 1994; Mitchell, 2001; Eldred et al, 2003;
Newman, 2003; Pearson et al, 2005; Reigada & Mitchell, 2005;
Reigada et al, 2005), which can act on P2X7R in the RPE cells via an
autocrine or a paracrine manner (Perez et al, 1986; Xia et al, 2012).
Yang et al (2011) reported that the P2X7R is expressed in both
native and cultured human RPE cells and its activation induces both
Ca2+ signaling and apoptosis in RPE cells. Furthermore, BzATP-
induced RPE apoptosis was blocked or significantly inhibited by
P2X7R antagonists BBG, KN-62, and oxidized ATP. Oxidized ATP,
an irreversible blocker of P2X7R, abrogates ATP-induced IL-1b
release from immune cells (Ferrari et al, 1997b). All of these above
suggest that the over-activation of P2X7R may contribute to the
development of GA.
Complement components Recently, Brandstetter et al (2015a)
showed that complement component C5a is a priming signal for the
NLRP3 inflammasome in RPE cells that mediates inflammasome
activation by lipofuscin/blue light-induced photo-oxidative damage.
There is also research showing that C1q represents an activation
signal for the NLRP3 inflammasome, acting in a caspase-1- and
phagolysosome-dependent manner in LPS-primed mouse bone
marrow-derived macrophages and THP1 human monocytic cells
(Doyle et al, 2012). In addition to C1q, C3a and MAC trigger
inflammasome activation (Asgari et al, 2013; Triantafilou et al,
2013). C3a induces NLRP3 inflammasome activation and IL-1b
secretion in human monocytes by controlling the release of intracel-
lular ATP into the extracellular space (Asgari et al, 2013). However,
sublytic MAC attack generates pores on the membrane that allow
Ca2+ influx, and thus increase cytosolic Ca2+ concentration,
triggering NLRP3 activation and IL-1b production (Triantafilou et al,
2013).
Amyloid-b Amyloid-b (Ab) is a component of drusen and has been
suggested as pathogenic factor in AMD (Johnson et al, 2002). It is a
pathogenic trigger peptide that induces inflammation and neurotoxi-
city in the retina. Intrinsic cytotoxicity of Ab is due to its aggregated
forms as soluble oligomers or insoluble fibrils (Gao et al, 2015). Ab
(1–40) and Ab(1–42) are the two most common isoforms of Ab,
which are recognized to be the most relevant forms to induce
neurodegeneration in amyloidosis (Zhang et al, 2012). Increasing
Ab(1–42) secretion was found in senescent ARPE-19 cells (Glotin
et al, 2008). Accumulating evidence suggests that increasing Ab
deposition with age may contribute to the development of AMD
(Johnson et al, 2002; Dentchev et al, 2003; Zhao et al, 2015b). In
addition to Ab’s cytotoxicity, NLRP3 inflammasome activation
induced by Ab may be responsible for RPE dysfunction. Halle et al
(2008) reported that NLRP3 inflammasome activation is initiated by
fibrillar Ab-induced lysosomal damage which increased release of
lysosomal protease cathepsin B in microglia. As a trigger, Ab stimu-
lates RPE cells and results in accelerating the secretion of IL-1b
(Kurji et al, 2010).
Alu RNA Alu RNA, a non-coding RNA transcribed from Alu
elements, plays a prominent role as gene modulator via genome
shaping, transcriptional regulation, and mRNA alternative splicing
(Hasler et al, 2007). Alu RNA accumulation secondary to DICER1
deficiency in the RPE has been implicated in GA (Tarallo et al,
2012). Kaneko et al (2011) showed that a reduction in RNase
DICER1 leads to accumulation of Alu RNA transcripts in the RPE of
GA patients. Delivery of a plasmid coding for Alu RNA upregulated
NLRP3 and IL-18 mRNAs in mouse RPE cells and induced ROS
production in human RPE cells (Tarallo et al, 2012). These results
suggest that Alu RNA triggers NLRP3 priming and mitochondrial
ROS in RPE cells. ERKs promote cell death in a variety of chronic
neurodegenerative states. Increased ERK1/2 phosphorylation was
observed in the RPE of human eyes with GA, and Alu RNA-induced
RPE degeneration in mice is rescued by intravitreous administration
of PD98059, an inhibitor of the ERK1/2-activating kinase MEK1
(Dridi et al, 2012). Thus, RPE degeneration induced by DICER1
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depletion or Alu RNA over-expression may be mediated by ERK1/2
signaling (Dridi et al, 2012). ERK1/2 signaling also regulates angio-
genesis and CNV (Hua et al, 2011; Xie et al, 2011). Therefore,
ERK1/2 activation is a potential target for both atrophic and neovas-
cular AMD.
Strategies for therapeutic modulation of inflammasome activation
IL-1b inhibitors IL-1b is a key inflammatory cytokine regulated by
the inflammasome, and increased levels of IL-1b are present in DR
(Kowluru et al, 2011; Liu et al, 2012) and AMD (Lavalette et al,
2011; Tarallo et al, 2012). Amelioration of IL-1b activation prevents
mitochondrial dysfunction and DNA damage (Kowluru et al, 2011).
Furthermore, glucose-induced apoptosis of retinal endothelial cells
is prevented by neutralization of IL-1b through incubating the cells
with an IL-1b antibody or IL-1b receptor antagonist (Kowluru &
Odenbach, 2004). The importance of IL-1b in retinal diseases makes
IL-1 inhibition a therapeutic option. The IL-1b receptor antagonist
anakinra (ANA), anti-IL-1b antibody canakinumab (CAN), and
recombinant humanized anti-IL-1b antibody gevokizumab (XOMA
052) have good clinical results in ocular diseases such as uveitis
secondary to Behc¸et’s disease (BD; Gul et al, 2012; Ugurlu et al,
2012; Vitale et al, 2014; Cantarini et al, 2015; Emmi et al, 2016).
ANA and CAN have been shown to be an effective and safe thera-
peutic option for BD-related refractory or long-standing uveitis with
a significant reduction in the rate of ocular inflammatory flare, reso-
lution of active retinal vasculitis, preservation of visual acuity, and
significant decrease in required steroid dosages (Fabiani et al,
2017). Ildefonso proposed that anti-inflammatory genes delivered
by an adeno-associated virus (AAV) vector could be used as poten-
tial treatments for retinal inflammation (Ildefonso et al, 2015). Eyes
injected with the caspase activation and recruitment domain
(CARD) AAV vector had a significant decrease in both IL-1b secre-
tion and infiltrating cells (Ildefonso et al, 2015). Data on the efficacy
of IL-1b inhibition therapy in inflammasome-related retinal diseases
are currently lacking.
NLRP3 inhibitors Direct inhibition of NLRP3 is an obvious
approach for suppressing inflammasome activity. Recently, a
small-molecule inhibitor MCC950 (also known as CRID3), which
is a diarylsulfonylurea-based compound, was reported to be a
potent and highly specific inhibitor of NLRP3, but not the AIM2,
NLRC4, and NLRP1 inflammasomes (Coll et al, 2015). Coll et al
(2015) reported that MCC950 could suppress both canonical and
non-canonical NLRP3 activation by preventing ASC complexes
instead of blocking K+ efflux, Ca2+ flux, or NLRP3–ASC interac-
tions. By reducing IL-1b and IL-18 secretion, the substance allevi-
ated the severity of EAE and cryopyrin-associated periodic
syndromes (CAPS) in mouse models. MCC950 thus is a potential
therapeutic for NLRP3-associated diseases. It has also been
reported in APP/PS1 mice, an AD model, that MCC950 suppresses
inflammasome activation and IL-1b production, stimulates Ab
phagocytosis in vitro, and reduces Ab accumulation (Dempsey
et al, 2017). With regard to the retina, MCC950 is capable of
inhibiting NLRP3 inflammasome activation and apoptosis in
human retinal endothelial cells (HRECs) under high-glucose
conditions, likely through downregulation of the Nek7–NLRP3
pathway (Zhang et al, 2017).
Another substance that inhibits NLRP3 is the ketone body
b-hydroxybutyrate (BHB; Youm et al, 2015). Unlike MCC950, BHB
blocks only the canonical NLRP3 inflammasome activation pathway
by preventing K+ efflux and reducing ASC oligomerization and
speck formation (Youm et al, 2015). It reduces IL-1b and IL-18
production in human monocytes and attenuates caspase-1 activation
and IL-1b secretion in mouse models of NLRP3-associated diseases,
such as Muckle–Wells syndrome, familial cold autoinflammatory
syndrome, and urate crystal-induced peritonitis. Both the
MCC950 and BHB hold promise as potential novel pharmaceutical
approach for treating DR, AMD, and other NLRP3-induced ocular
diseases.
Nucleoside reverse transcriptase inhibitors Nucleoside reverse
transcriptase inhibitors (NRTIs) are widely used to treat AIDS by
blocking HIV replication. Fowler et al (2014) discovered that NRTIs
inhibit P2X7-mediated NLRP3 inflammasome activation indepen-
dent of reverse transcriptase inhibition. Clinically relevant NRTIs
such as lamivudine (3TC), stavudine (d4T), and abacavir (ABC)
were shown to block caspase-1 activation induced by Alu RNA in
RPE cells (Fowler et al, 2014). Furthermore, NRTIs were efficacious
in mouse models of GA and choroidal neovascularization. Intravit-
reous injection of the NRTIs 3TC, zidovudine (AZT), and ABC
significantly suppressed laser-induced CNV and VEGF-A secretion in
wild-type mice but not P2rx7/ mice (Mizutani et al, 2015). This
suggests NRTIs as a possible new therapeutic approach for both dry
and wet AMD.
Conclusion
In the current review, we point out the fundamental similarity
between AMD, DR, and hereditary retinopathies (using the exam-
ple of RP)—and possible other retinal diseases as well—namely
non-resolving and overwhelming inflammation. We pointed out
three arms of inflammation which are activation of (i) mononu-
clear phagocytes, (ii) the complement system, and (iii) the
inflammasome. All three arms are intertwined and cannot be
treated exclusively without affecting each other, hence represent-
ing an attractive therapy target. Complement receptors are
expressed on MPs while NLRP inflammasomes lead to IL-1b acti-
vation and secretion contributing significantly to microglial activa-
tion and macrophage recruitment. Perturbations of immune-
suppressive capacities of the RPE, retinal neurons, and macroglia
due to aging, hyperglycemia, or other defects evoked by genetic
risk variants lead to non-resolving inflammation. Hence, the
proposed therapeutic options are auspicious approaches to start
with.
Pending issues
(i) Experimental studies on separating retinal immune cell popula-
tions.
(ii) Linking retinal microglia and macrophage phenotypes and func-
tions with disease outcome.
(iii) Identifying optimal targets in the complement cascade.
(iv) Clinical studies with immunomodulatory compounds.
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